Stocks of Replimune Group Inc (NASDAQ:REPL) traded higher last session on Wall Street, up 1.85% to $12.63.
REPL stock price is now 35.93% away from the 50-day moving average and 14.30% away from the 200-day moving average. The market capitalization of the company currently stands at $973.61M.
On August 28, 2024, ROTH MKM recently initiated its ‘Buy’ rating on the stock quoting a target price of $17, while ‘Piper Sandler’ rates the stock as ‘Overweight’
In other news, Astley-Sparke Philip, Director sold 32,279 shares of the company’s stock on May 20 ’25. The stock was sold for $260,169 at an average price of $8.06. Upon completion of the transaction, the Director now directly owns 1,405,071 shares in the company, valued at $17.75 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 20 ’25, Chief Medical Officer Xynos Konstantinos sold 7,952 shares of the business’s stock. A total of $64,093 was realized by selling the stock at an average price of $8.06. This leaves the insider owning 146,933 shares of the company worth $1.86 million. A total of 18.88% of the company’s stock is owned by insiders.
During the past 12 months, Replimune Group Inc has had a low of $6.44 and a high of $17.00. As of last week, the company has a debt-to-equity ratio of 0.18, a current ratio of 7.95, and a quick ratio of 7.95. The fifty day moving average price for REPL is $9.184 and a two-hundred day moving average price translates $11.0353 for the stock.
The latest earnings results from Replimune Group Inc (NASDAQ: REPL) was released for 2025-03-31. The company reported revenue of $79.33 million for the quarter, compared to $58.75 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 35.01 percent. For the current quarter, analysts expect REPL to generate $1.32M in revenue.
